Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2020 - 12 - 21 save search
Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Published: 2020-12-21 (Crawled : 20:11) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -1.63%
H: 2.32%
C: 1.34%
license leukemia submission treatment
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation
Published: 2020-12-21 (Crawled : 16:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 16.12%
H: 0.18%
C: -7.82%
cancer phase 3 therapy ovarian cancer
Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
Published: 2020-12-21 (Crawled : 15:00) - biospace.com/
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: -0.94%
H: 2.89%
C: -0.05%
approval therapy gene therapies trial phase 3 phase 1 phase 2 gene therapy tsha-102
New Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12™ for the Treatment of Cancer
Published: 2020-12-21 (Crawled : 14:03) - globenewswire.com
CDAK | $0.057 -55.99% -131.25% 0
|
Health Technology
|
| O: -2.41%
H: 24.03%
C: 22.4%
cancer molecular treatment preclinical pre-clinical
PGG Wrightson Seeds to Distribute Marrone Bio Innovations’ Pro Farm UBP Seed Treatment in Uruguay
Published: 2020-12-21 (Crawled : 14:00) - globenewswire.com
MBII | $0.7981 -20.19% 1.49%
|
Process Industries
|
| O: -7.97%
H: 8.66%
C: 4.72%
seeds treatment distribution
Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2020-12-21 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.62%
H: 0.92%
C: 0.66%
fda license therapy car-t submission cel
Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2020-12-21 (Crawled : 14:00) - biospace.com/
LEGN | $46.14 -2.08% -2.12% 1.2M
|
Health Technology
|
| O: -2.15%
H: 2.64%
C: -0.7%
fda approval biotech license therapy car-t submission cel
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
AGIO | $29.52 0.31% 0.3% 750K
|
Health Technology
|
| O: 32.83%
H: 4.07%
C: -3.38%
disease royalties treatment commercialization
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 2.43%
H: 3.76%
C: -7.52%
approval treatment libmeldy
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
Published: 2020-12-21 (Crawled : 12:01) - globenewswire.com
BCRX | $4.44 -1.33% -1.35% 4.7M
|
Health Technology
|
| O: 0.58%
H: 0.75%
C: -4.16%
results positive treatment phase 3 phase 1 phase 2
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Published: 2020-12-21 (Crawled : 12:00) - biospace.com/
APM | $5.9 9.87% 8.98% 37K
|
Health Technology
|
| O: 0.76%
H: 4.53%
C: -0.75%
drug trial submission injection als infections staphylococcus aureus
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
Published: 2020-12-21 (Crawled : 00:12) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 2.67%
H: 1.3%
C: -3.25%
fda approval fda approval therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.